FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007667017> ?p ?o ?g. }

• W2007667017 endingPage "1004" @default.
• W2007667017 startingPage "993" @default.
• W2007667017 abstract "Tadalafil is a phosphodiesterase-5 (PDE-5) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2009 for the treatment of pulmonary arterial hypertension (PAH).The purpose of this review is to evaluate the pharmacology, pharmacokinetic properties, clinical efficacy, adverse effects, drug interactions, and dosage and administration of tadalafil in patients with PAH.A literature search of MEDLINE and International Pharmaceutical Abstracts (1960 through September 5, 2010) was conducted with the search terms tadalafil, pulmonary arterial hypertension, and phosphodiesterase-5 inhibitor. Data found from orignial research and case series published in English were screened for relevancy to pharmacology, pharmacokinetics, clinical efficacy and safety, and tolerability. Relevant articles from the bibliographies of the identified published articles were also obtained. Unpublished data and posters were obtained from the manufacturer of tadalafil and the FDA Web site.By selectively inhibiting PDE-5, tadalafil causes nitric oxide-mediated vasodilation in the pulmonary vasculature. Tadalafil has a greater affinity (10,000-fold) for PDE-5 compared with the other PDE inhibitors and has a t(½) of 17.5 hours. In a controlled clinical study in patients with PAH, patients receiving tadalafil in a total daily dose of 40 mg had significant improvements in their 6-minute walk distance (33 m from baseline) and time to clinical worsening compared with those receiving placebo (both, P < 0.05). Tadalafil had adverse effects similar to placebo, with headache being the most commonly reported (42%).In the small number of studies available, tadalafil was effective and well tolerated when used to treat patients with PAH. Compared with placebo, tadalafil was associated with significant improvements in exercise capacity and reduced time to clinical worsening (68% relative risk reduction; P = 0.038). There is limited evidence comparing tadalafil with sildenafil and vardenafil, and the studies are limited by short treatment durations." @default.
• W2007667017 created "2016-06-24" @default.
• W2007667017 creator A5014862518 @default.
• W2007667017 creator A5039930884 @default.
• W2007667017 date "2011-08-01" @default.
• W2007667017 modified "2023-09-26" @default.
• W2007667017 title "Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension" @default.
• W2007667017 cites W1567859570 @default.
• W2007667017 cites W1975033578 @default.
• W2007667017 cites W1975119053 @default.
• W2007667017 cites W1975268388 @default.
• W2007667017 cites W1976294230 @default.
• W2007667017 cites W1980732197 @default.
• W2007667017 cites W1989435406 @default.
• W2007667017 cites W1994219663 @default.
• W2007667017 cites W1995587221 @default.
• W2007667017 cites W1996141149 @default.
• W2007667017 cites W1997713908 @default.
• W2007667017 cites W2001083144 @default.
• W2007667017 cites W2001706988 @default.
• W2007667017 cites W2012400171 @default.
• W2007667017 cites W2025593289 @default.
• W2007667017 cites W2027227731 @default.
• W2007667017 cites W2027244911 @default.
• W2007667017 cites W2038393150 @default.
• W2007667017 cites W2048017693 @default.
• W2007667017 cites W2067313134 @default.
• W2007667017 cites W2070022895 @default.
• W2007667017 cites W2070286718 @default.
• W2007667017 cites W2085617221 @default.
• W2007667017 cites W2091088413 @default.
• W2007667017 cites W2091862472 @default.
• W2007667017 cites W2101386214 @default.
• W2007667017 cites W2103763164 @default.
• W2007667017 cites W2119718845 @default.
• W2007667017 cites W2121376498 @default.
• W2007667017 cites W2127994875 @default.
• W2007667017 cites W2128020166 @default.
• W2007667017 cites W2128868945 @default.
• W2007667017 cites W2132288985 @default.
• W2007667017 cites W2139954704 @default.
• W2007667017 cites W2141987653 @default.
• W2007667017 cites W2148038451 @default.
• W2007667017 cites W2148225708 @default.
• W2007667017 cites W2148797779 @default.
• W2007667017 cites W2153625446 @default.
• W2007667017 cites W2159885935 @default.
• W2007667017 cites W2160056424 @default.
• W2007667017 cites W2164844212 @default.
• W2007667017 cites W2166777622 @default.
• W2007667017 doi "https://doi.org/10.1016/j.clinthera.2011.06.008" @default.
• W2007667017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21762988" @default.
• W2007667017 hasPublicationYear "2011" @default.
• W2007667017 type Work @default.
• W2007667017 sameAs 2007667017 @default.
• W2007667017 citedByCount "33" @default.
• W2007667017 countsByYear W20076670172012 @default.
• W2007667017 countsByYear W20076670172013 @default.
• W2007667017 countsByYear W20076670172014 @default.
• W2007667017 countsByYear W20076670172015 @default.
• W2007667017 countsByYear W20076670172016 @default.
• W2007667017 countsByYear W20076670172017 @default.
• W2007667017 countsByYear W20076670172018 @default.
• W2007667017 countsByYear W20076670172019 @default.
• W2007667017 countsByYear W20076670172020 @default.
• W2007667017 countsByYear W20076670172021 @default.
• W2007667017 countsByYear W20076670172022 @default.
• W2007667017 crossrefType "journal-article" @default.
• W2007667017 hasAuthorship W2007667017A5014862518 @default.
• W2007667017 hasAuthorship W2007667017A5039930884 @default.
• W2007667017 hasConcept C112705442 @default.
• W2007667017 hasConcept C126322002 @default.
• W2007667017 hasConcept C142724271 @default.
• W2007667017 hasConcept C197934379 @default.
• W2007667017 hasConcept C204787440 @default.
• W2007667017 hasConcept C27081682 @default.
• W2007667017 hasConcept C2776768464 @default.
• W2007667017 hasConcept C2778375690 @default.
• W2007667017 hasConcept C2780035454 @default.
• W2007667017 hasConcept C2780816001 @default.
• W2007667017 hasConcept C2780930700 @default.
• W2007667017 hasConcept C42219234 @default.
• W2007667017 hasConcept C535046627 @default.
• W2007667017 hasConcept C71924100 @default.
• W2007667017 hasConcept C74534348 @default.
• W2007667017 hasConcept C98274493 @default.
• W2007667017 hasConceptScore W2007667017C112705442 @default.
• W2007667017 hasConceptScore W2007667017C126322002 @default.
• W2007667017 hasConceptScore W2007667017C142724271 @default.
• W2007667017 hasConceptScore W2007667017C197934379 @default.
• W2007667017 hasConceptScore W2007667017C204787440 @default.
• W2007667017 hasConceptScore W2007667017C27081682 @default.
• W2007667017 hasConceptScore W2007667017C2776768464 @default.
• W2007667017 hasConceptScore W2007667017C2778375690 @default.
• W2007667017 hasConceptScore W2007667017C2780035454 @default.
• W2007667017 hasConceptScore W2007667017C2780816001 @default.
• W2007667017 hasConceptScore W2007667017C2780930700 @default.
• W2007667017 hasConceptScore W2007667017C42219234 @default.

• next